sj-jpg-3-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-3-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-2-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-2-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-6-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-6-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-7-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-7-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-4-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-4-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-5-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-5-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-docx-1-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-docx-1-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p